Reach Neuro
The first and only treatment option for chronic stroke patients to move again voluntarily
Reach Neuro is active in the biopharma space based in Great Lakes, Northeastern US, founded in 2021.
Profile
More info at the IndieBio website At Reach Neuro, Inc. we don’t believe that disability due to chronic stroke should mean an end to independence or the ability to participate in the activities you love. We are developing the first-ever treatment for upper-limb paralysis caused by stroke. Our technology uses an implantable neuromodulator to stimulate the spinal cord, working with the nervous system to restore motor function, even 9 years post-stroke.
The company sits in the biopharma segment, where it competes on its core product or service.
Its base of operations is Great Lakes, Northeastern US.
The company is listed at the SOSV portfolio company stage of development.
The company reports a headcount in the 2-10 range.
Total disclosed funding stands at about $965K.
| Sector | Biopharma |
|---|---|
| Headquarters | Great Lakes, Northeastern US |
| Country | United States |
| Founded | 2021 |
| Employees | 2-10 |
| Stage | SOSV portfolio company |
| Total funding | $965,000 |
Website: reachneuro.com
Create a free account